Vaxess Technologies has received the final tranche of its $8.2m series A round led by MIT-affiliated incubator and venture capital fund The Engine.

Vaxess Technologies, a US-based drug delivery patch developer based on research at Massachusetts Institute of Technology (MIT) and Tufts University, has closed an $8.2m series A round led by The Engine.

Bioinnovation Capital also backed the round, which was raised over multiple tranches, though further details were not revealed. The Engine is an incubator and venture capital fund launched by MIT in 2016.

Founded in 2012, Vaxess is working on a smart drug delivery patch, Mimix, that relies on silk…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).